JPRN-jRCT2031230090招募中1 期
A Phase I Study of OTS167PO, a MELK inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients with Advanced Breast Cancer and Dose-Expansion Study in Patients with Triple Negative Breast Cancer. - OTS1070103
Manabu Ishizuka0 个研究点目标入组 70 人开始时间: 2023年5月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Dose Escalation and Dose Expansion Cohorts
- •1.Female patients, >= 18 years of age at the time of obtaining informed consent.
- •2.Patients with a documented (histologically or cytologically proven) breast cancer that is locally advanced or metastatic.
- •3.Patients with a malignancy that is either relapsed/refractory to standard therapy or for which no standard therapy is available.
- •4.Patients with a malignancy that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor.
- •5.Patients with measurable or non measurable disease according to the Response Evaluation Criteria In Solid Tumor (RECIST, v1.1).
- •6.Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (see APPENDIX B: Performance Status Evaluation).
- •7.Life expectancy of greater than or equal to 3 months.
- •8.Resolution of all chemotherapy-related or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy (less than or equal to Grade 2).
- •9.Patients who are either not of childbearing potential or who agree to use a medically effective method of contraception during the study and during 3 months after the last dose of study drug. (See Appendix H: Forms of contraception).
- •10.Patients with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.
- •Dose expansion Cohort for TNBC
- •1.Patients with conditions as follows;
- •ER <10%, PR <10% by IHC assay, and HER2 negative based on ASCO CAP guideline
- •2.Patients with measurable disease according to the response evaluation criteria in TNBC (RECIST, v1.1)
- •3.Patients with measurable disease that can be easily accessed for biopsy.
- •4.Relapsed (recurrence or disease progression after achieving a documented clinical response to first- or second-line treatment) or refractory (disease progression while receiving first line or second line treatment). In the case of TNBC, prior initial therapy with at least one known active regimen for TNBC including, but not limited to, any combination of anthracyclines, taxanes, platinum agents, Ixabepilone, and/or cyclophosphamide is required.
排除标准
- •Dose Escalation and Expansion Cohorts
- •1.Women who are pregnant or lactating. Women of child-bearing potential (WOCBP) not using adequate birth control see Appendix H: Forms of contraception.
- •2.Patients with known central nervous system (CNS) or leptomeningeal metastases not controlled by prior surgery, radiotherapy or requiring corticosteroids to control symptoms, or patients with symptoms suggesting CNS involvement for which treatment is required.
- •3.Patients with primary brain tumors.
- •4.Patients with any hematologic malignancy. This includes leukemia (any form), lymphoma, and multiple myeloma.
- •5.Patients with any of the following hematologic abnormalities at baseline. (Patients may have received a red blood cell product transfusion prior to study, if clinically warranted.):
- •-Absolute neutrophil count (ANC) < 1,500 per mm3
- •-Platelet count < 100,000 per mm3
- •-Hemoglobin < 8.0 gm/dL
- •6.Patients with any of the following serum chemistry abnormalities at baseline:
- •-Total bilirubin >= 1.5 times the ULN for the institution value
- •-AST or ALT >= 3 times the ULN for the institution value (>= 5 times if due to hepatic involvement by tumor)
- •-Creatinine >= 1.5 times ULN for the institution value (or a calculated creatinine clearance < 60 mL/min/1.73 m2)
- •7.Patients with a significant active cardiovascular disease or condition, including:
- •-Congestive heart failure (CHF)requiring therapy
- •-Need for antiarrhythmic medical therapy for a ventricular arrhythmia
- •-Severe conduction disturbance
- •-Unstable angina pectoris requiring therapy
- •-QTc interval > 450 msec (males) or > 470 msec (females)
- •-QTc interval =< 300 msec
- •-History of congenital long QT syndrome or congenital short QT syndrome
- •-LVEF < 50% as measured by echocardiography or MUGA scan
- •-Uncontrolled hypertension (per the Investigator's discretion)
- •-Class III or IV cardiovascular disease according to the New York Heart Association's (NYHA) Functional Criteria (see APPENDIX C: New York Heart Association's Functional Criteria).
- •-Myocardial infarction (MI) within 6 months prior to first study drug administration
- •8.Patients with a known or suspected hypersensitivity to any of the components of OTS167.
- •9.Patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
- •10.Patients with any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38 degrees within 1 week prior to first study drug administration.
- •11.Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to first study drug administration.
- •12.Patients with any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug.
- •13.Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.
- •14.Patients with the inability or with foreseeable incapacity, in the opinion of the Investigator, to comply with the protocol requirements.
- •15.Any anti-neoplastic agent or monoclonal antibody therapy
研究者
相似试验
招募中
1 期
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast CancerNCT02926690OncoTherapy Science, Inc.70
进行中（未招募）
1 期
A Phase 1/2 Clinical Trial of Pediatric Cancer Patients With Solid Tumors Treated with LOXO-101Central Nervous System Neoplasms and advanced solid tumorsMedDRA version: 20.0Level: LLTClassification code 10049516Term: Malignant tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10007959Term: Central nervous system neoplasm NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10007958Term: Central nervous system neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: HLTClassification code 10007960Term: Central nervous system neoplasms malignant NECSystem Organ Class: 100000004852EUCTR2016-003498-16-FRoxo Oncology Inc.84
进行中（未招募）
1 期
A Phase 1/2 Clinical Trial of Pediatric Cancer Patients With Solid Tumors Treated with LOXO-101EUCTR2016-003498-16-ESoxo Oncology Inc.84
进行中（未招募）
1 期
A phase 1/2 study of the investigational treatment LOXO-195 in adults and minors that have a previously treated cancer with a change in a gene called NTRK.EUCTR2017-004246-20-ITBayer Consumer Care AG103
进行中（未招募）
1 期
A phase 1/2 study of the investigational treatment LOXO-195 in adults and minors that have a previously treated cancer with a change in a gene called NTRK.TRK fusion cancers previously treated with a TRK inhibitorMedDRA version: 20.0Level: LLTClassification code 10049516Term: Malignant tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10007958Term: Central nervous system neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004246-20-FRoxo Oncology, Inc103